|
| CD19+ B cells | CD3+ T cells | CD4+ T cells | CD8+ T cells | CD4+25+127low+ Treg cells | CD3+4+45RA+ naïve T cells | CD3−16+56+ NK cells |
|
At onset of disease (6 months of age) | 12%, 1,430 cells/mcL (50–75pc) | 82%, 9,700 cells/mcL (>95pc) | 63%, 7,500 cells/mcL (>95pc) | 17%, 2,000 cells/mcL (90–95pc) | 8% of CD4+ T cells, 344 cells/mcL (10–90pc) | 66% | 5%, 600 cells/mcL (50–75 pc) |
3 mo after the first HSCT (13 months of age), 15% donor cells on total chimerism | 0% | 61%, 1,150 cells/mcL (<5pc) | 19%, 360 cells/mcL (<5pc) | 27%, 530 cells/mcL (10–25pc) | ND | 2% | 29%, 560 cells/mcL (75pc) |
24 mo after the second HSCT (3.5 years of age), 65% of donor cells on total chimerism | 11%, 250 cells/mcL (<5pc) | 81%, 1,830 cells/mcL (25pc) | 47%, 1,000 cells/mcL, (25pc), 78% donor | 22%, 490 cells/mcL (5–10pc), 97% donor | 4% of CD4+ T cells, 40 cells/mcL (10–90pc), 91% donor | 48% | 3%, 70 cells/mcL (<5pc) |
|